Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$120,000.00

Investigating the Role of microRNA in Colorectal Cancer Drug-Tolerant Persister State

EF 2024-25

Résumé
Colorectal cancer (CRC) is the third leading cause of all cancer-related deaths in North America. In total, 40% of CRC patients develop metastasis. We know that long-term drug treatment is very toxic to the body, and the cancer will eventually adapt and develop drug resistance. In the clinic, we observed an interesting phenomenon. CRC patients may initially respond well to chemotherapy. When treatment stops, they experience tumor regrowth but respond again when chemotherapy restarts. Imagine these cancer cells are like hibernating bears. When the threat (chemotherapy) is lifted off, they wake up and start hunting (cancer grows). This hibernating or drug-tolerant persister (DTP) state could be a novel opportunity to attack cancer right before the patient develops permanent drug resistance. Currently, we do not know whether microRNAs (miRNAs) play a role in the DTP state. However, the drastic change in gene expression in CRC DTPs and miRNA's ability to coordinate the simultaneous expression/inhibition of multiple genes made it an area worthy of exploration. Therefore, we hypothesize that miRNAs play a key role in coordinating entry into the CRC DTP state. The goal of this work is to identify novel miRNA and its functional role in driving CRC DTP state, and to guide the development of biomarkers to know if patients are at a higher risk of relapse, as well as miRNA-targeted therapeutics that are specific to the state.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
518279
Name
Kwan Ka Yu Carissa
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating the Role of microRNA in Colorectal Cancer Drug-Tolerant Persister State
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Colorectal Cancer; Crispr-Cas9 Screen; Drug-Tolerant Persisters; Microrna; Patient-Derived Xenograft; Rna Therapeutics; Rna-Sequencing
Abstract
Colorectal cancer (CRC) is the third leading cause of all cancer-related deaths in North America. In total, 40% of CRC patients develop metastasis. We know that long-term drug treatment is very toxic to the body, and the cancer will eventually adapt and develop drug resistance. In the clinic, we observed an interesting phenomenon. CRC patients may initially respond well to chemotherapy. When treatment stops, they experience tumor regrowth but respond again when chemotherapy restarts. Imagine these cancer cells are like hibernating bears. When the threat (chemotherapy) is lifted off, they wake up and start hunting (cancer grows). This hibernating or drug-tolerant persister (DTP) state could be a novel opportunity to attack cancer right before the patient develops permanent drug resistance. Currently, we do not know whether microRNAs (miRNAs) play a role in the DTP state. However, the drastic change in gene expression in CRC DTPs and miRNA's ability to coordinate the simultaneous expression/inhibition of multiple genes made it an area worthy of exploration. Therefore, we hypothesize that miRNAs play a key role in coordinating entry into the CRC DTP state. The goal of this work is to identify novel miRNA and its functional role in driving CRC DTP state, and to guide the development of biomarkers to know if patients are at a higher risk of relapse, as well as miRNA-targeted therapeutics that are specific to the state.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kwan, Ka Yu Carissa
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~